iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Reaches New 12-Month High at $120.36

iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) reached a new 52-week high on Wednesday . The stock traded as high as $120.36 and last traded at $120.30, with a volume of 1110281 shares traded. The stock had previously closed at $119.15.

Separately, ValuEngine lowered iShares Nasdaq Biotechnology ETF from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd.

The business has a fifty day moving average of $111.03 and a 200 day moving average of $105.86.

A number of large investors have recently added to or reduced their stakes in the stock. HM Payson & Co. bought a new position in iShares Nasdaq Biotechnology ETF in the 2nd quarter worth $36,000. Signaturefd LLC lifted its position in shares of iShares Nasdaq Biotechnology ETF by 59.2% in the 2nd quarter. Signaturefd LLC now owns 328 shares of the financial services provider’s stock worth $36,000 after purchasing an additional 122 shares during the period. Horan Capital Advisors LLC. bought a new stake in shares of iShares Nasdaq Biotechnology ETF during the 3rd quarter valued at about $34,000. Capital Planning Advisors LLC bought a new stake in shares of iShares Nasdaq Biotechnology ETF during the 3rd quarter valued at about $36,000. Finally, Oakworth Capital Inc. increased its position in shares of iShares Nasdaq Biotechnology ETF by 171.4% during the second quarter. Oakworth Capital Inc. now owns 475 shares of the financial services provider’s stock valued at $52,000 after buying an additional 300 shares during the period. Institutional investors and hedge funds own 82.74% of the company’s stock.

iShares Nasdaq Biotechnology ETF Company Profile (NASDAQ:IBB)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading: Current Ratio

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.